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Abstract
Background: Seizure control doesn't represent the only challenging goal in patients with brain
tumor-related epilepsy. Side effects have often taken precedence for patients' quality of life.
Methods: We performed an observational retrospective study on patients with brain tumor-
related epilepsy: 35 who had assumed oxcarbazepine monotherapy and 35 patients who had
undergone treatment with traditional antiepileptic drugs. Primary variable of efficacy was the mean
seizure frequency per month and safety variables were the drop-out for side effects and total
incidence of side effects. We applied the Propensity Score technique to minimize selection bias.
Results: Our results showed a similar efficacy of oxcarbazepine and traditional antiepileptic drugs
over time, but the difference in safety and tolerability between the two groups was significant:
traditional AEDs caused more side effects, both serious and non serious.
Conclusion: This study highlights the importance of taking into consideration not only seizure
control but also the appearance of side effects when choosing antiepileptic drugs in this patients
population.
Background
Seizures are a common symptom in patients with brain
tumors [1]. Literature data on antiepileptic drugs (AEDs)
in brain tumor patients indicate that not only complete
seizure control is a challenging goal [2] but that reducing
unpleasant side effects produced by AEDs is a serious con-
cern as well [3]. Side effects are mostly associated with the
administration of traditional, older antiepileptic drugs:
carbamazepine (CBZ), phenobarbital (PB), phenytoin
(PHT) and valproic acid (VPA) [3-7]. Some limited data in
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the literature indicate that side effects are less marked
when the newer AEDs such as oxcarbazepine, levetira-
cetam, topiramate, gabapentin and pregabalin are admin-
istered [6-13]. However, there have been no comparative
studies to date which document the differences in efficacy
and tolerability between the newer and older AEDs. The
aim of this study was to assess if one of the newer genera-
tion AEDs presented significant differences in terms of
efficacy as well as safety/tolerability when compared to
the traditional AEDs, in patients with brain-tumor related
epilepsy.
We chose not to undertake a comparative prospective
study using traditional AEDs versus new AEDs, because
substantial data indicate high toxicity of traditional AEDs
and their interactions with chemotherapeutic agents
strong enough to shorten life expectancy [7,14-18]. There-
fore, we preferred to compare two retrospective groups,
one in therapy with traditional AEDs and one with a new
generation AED – oxcarbazepine – in order to assess if
there were differences in efficacy and tolerability.
We choose a retrospective group of patients treated with
oxcarbazepine because its efficacy is similar to that
observed with the old AEDs [19], but, the low induction
of CYP enzymes by OXC is associated with lower pharma-
cological interaction than other drugs. For this reason,




We made a retrospective chart review for 35 brain tumor
patients who were followed in our Institute because of
brain tumor and epilepsy during the period 1995 to
December 2005 (the last date which had been docu-
mented in the medical charts). These patients had been in
treatment with traditional AEDs (Traditional AEDs group).
We chose those patients whose age, sex and duration of
AED treatment were similar to the OXC group.
We conducted a retrospective chart review on 35 patients
with brain tumor and epilepsy who came to our Center
during the period January, 2002 to February, 2007 in
order to evaluate the efficacy and tolerability of OXC
monotherapy (OXC group). Data were collected from
medical charts until June 2007 (data chosen for the end of
the study).
We compared the Traditional AED group to the OXC
group in order to assess if there were differences in efficacy
and tolerability.
The study was approved by the Institute's Ethical Commit-
tee.
Selection of patients
Patients with brain tumor related epilepsy were included
in the study if: between the ages 18 and 85; if they had had
a KPS ≥ 60; if they had received a diagnosis of their disease
(primary brain tumors or metastatic brain tumors) after
surgical intervention or radiological diagnosis. Patients
were eligible for inclusion if they had experienced at least
one observable seizure in the last year, prior to screening.
Patients with epilepsy unrelated to brain tumor were
excluded from the study. The following information was
collected for each patient, at baseline and during the his-
tory of disease: surgery, type of chemotherapy, radiother-
apy, presence of a tumoral progression.
Assessment methods
Traditional AED group and OXC group
A retrospective chart review was conducted on 35 brain
tumor patients who had received PB, CBZ, PHT or VPA
monotherapy for seizure control and on 35 brain tumor
patients who had received OXC monotherapy for seizure
control at our Center. These patients had arrived at our
Center: 1) for uncontrolled seizures and/or side effects
which had been caused by previous AED therapy 2) soon
after the diagnosis of epilepsy related to brain tumor,
without having had any prior AED therapy. Seizure fre-
quency (SF) was assessed based on number of seizures
documented in patient histories, hospital charts, and
clinic notes. The appearance of side effects was assessed by
using clinical notes and hospital charts. The severity of the
AED's side effects was evaluated using the "Common Ter-
minology Criteria for Adverse Events" [22].
Statistical analyses
The aim of the study was to conduct a comparative analy-
sis between the treatment groups: A) OXC Group and B)
Traditional AED Group in order to evaluate the efficacy in
controlling seizures as well as the safety and tolerability of
the AEDs. The primary efficacy variable which we used
was the mean number of seizures per month. The safety
variables used were both the drop-out for side effects as
well as the total incidence of side effects.
In order to subject our data to statistical analyses, it was
necessary to create homogeneity between the two treat-
ment groups (OXC and Traditional AEDs). This was done
by applying a Propensity Score (PS), even though this
technique is primarily used for larger samples. A PS is used
by identifying co-variables in both groups to insert in the
logistic regression model. Seven co-variables useful for the
analysis were identified: age, sex, tumor progression, KPS,
chemotherapy, seizure frequency at base visit, follow-up
duration. The statistical analysis of efficacy between treat-
ment groups was applied using a General Linear Model
for fixed factors (GLM), taking into consideration the fol-
lowing factors: 1) Treatment Group (OXC versus Tradi-Journal of Experimental & Clinical Cancer Research 2009, 28:60 http://www.jeccr.com/content/28/1/60
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tional AEDs) 2) Visit (baseline versus final follow-up) 3)
Interaction between Treatment Group and Visit. The PS
was applied only for the analysis of efficacy between treat-
ment groups, and not for the safety/tolerability compari-
son between groups. For the analysis of safety variables
(drop-out incidence and total incidence of side effects) we
used the Fisher Exact Test taking into consideration the
number of patients who had left the study or who had had
side-effects.
The changes of SF from baseline to the final follow-up
visit were evaluated using statistical analysis on the intent-
to-treat (ITT) population (that is patients who had had at




Patients' demographic and clinical characteristic are
depicted in table 1 [see additional file 1].
Sixteen (16) had had glioblastoma multiforme (GBM), 5
anaplastic astrocytoma (AA), 4 anaplastic oligodendrogli-
oma (AO), 8 low grade astrocytoma (LGA) and 2 low
grade oligodendroglioma (LGO). Fourteen patients had
undergone only chemotherapy during the follow up, 7
patient had undergone only radiotherapy, 11 chemother-
apy and radiotherapy and 3 patients had not undergone
any systemic therapy. Eight patients had had tumoral pro-
gression during follow up.
The mean age at diagnosis of brain tumor was 50.1 years
(range 22 to 76 years). Nine patient had had simple par-
tial seizures (SP), 9 had had complex partial (CP), 3 had
had SP + secondarily generalized tonic clonic seizures
(SP+SGTC) and 14 had had CP+SGTC seizures. Patients
had all been in monotherapy with traditional AEDs: PB
(N = 24); CBZ (N = 9); VPA (N = 1), PHT (N = 1). Mean
dosages: PB = 112.5 mg/day, CBZ = 800 mg/day, VPA
1000 mg/day (only 1 patient), PHT 200 mg/day (only 1
patient) [see additional file 1].
Efficacy
The mean seizure frequency per month before AED treat-
ment had been 4.1 (35 patients) and 1.6 (35 patients) at
final follow up. At final follow up, 45.7% of patients (16
patients) were seizure free. GLM repeated measure analy-
sis showed a significant reduction of seizure frequency at
final follow-up (p = 0.0095). Mean duration of follow up
was 13.7 months (range 2 to 48 months).
Adverse Events
During treatment fifteen patients (42.9%) had reported
side effects: 11 patients in therapy with PB, 3 with CBZ
and 1 with VPA. Two patients (5.7%), all in therapy with
CBZ, had had mild and reversible side effects (haemato-
logical toxicity) and 13 patient (37.2%) had had heavy
side effects: 5 psychomotor slowness (4 patients with PB
and 1 with VPA), 4 rash (all patient with PB), 2 periarthri-
tis (all patients with PB), 1 somnolence (patient with PB)




Patients' demographic and clinical characteristic are
depicted in table 3 [see additional file 3].
Twelve patients had brain metastases, 4 GBM, 10 AA, 1
OA, 6 LGA and 2 meningioma. During follow up, 6
patients had undergone only chemotherapy, 3 patients
had undergone only radiotherapy, 23 patients had under-
gone both chemotherapy and radiotherapy and 3 patients
had not undergone any systemic therapy. Fourteen
patients had had tumoral progression. The mean age at
diagnosis of brain tumor was 52 years (range 18 to 81
years).
Eleven patients had had SP seizures, 4 had had CP, 6 had
had SP+SGTC and 14 had had CP+SGTC seizures.
Eighteen patients had already been treated with other
AEDs: PB = 14; CBZ = 3; topiramate – TPM- (N = 1) that
had been changed to OXC for heavy side effects (8
patients), uncontrolled seizures (9 patients) and 1 for
uncontrolled seizures and heavy side effects. Mean dos-
ages had been: PB = 103.6 mg/day, CBZ = 466.70 mg/day,
TPM 150 (only 1 patient). Seventeen had been naïve
patients. During the period considered for the study,
patients had all been in monotherapy with OXC with a
mean daily dosage of 1162.5 mg [See additional file 4].
Efficacy
The mean seizure frequency per month before OXC ther-
apy had been 2.9, and at the final follow-up had been 0.6
(35 patients). Considering separately the two subgroups
naive patients versus patients presenting for side effects/
inefficacy, the mean seizure frequency per month before
OXC therapy had been 4.64 (naïve patients, 17 patients)
and 1.3 (non-naïve patients, 18 patients). At the final fol-
low-up the mean seizure frequency had been 0.88 (naïve
patients) and 0.4 (non-naïve patients). At final follow up,
we obtained 62.9% patients who were seizure free (22
patients). GLM repeated measure analysis showed a sig-
nificant reduction of seizure frequency at final follow-up
(p = 0.0018). Mean duration of follow up was 16.1
months (range 4 to 48 months).Journal of Experimental & Clinical Cancer Research 2009, 28:60 http://www.jeccr.com/content/28/1/60
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Adverse Events
During follow up 4 patients (11.4%) reported side effects:
1 patient (2.9%) had had mild and reversible side effects
(mild rash and liver toxicity) and 3 (8.6%) had had heavy
side effects (2 rash and 1 cephalea) [See additional file 4].
Comparison between the two groups
Efficacy
In order to compare monthly seizure frequency in both
groups we used GLM repeated measure analysis with var-
iables: treatment groups (Traditional AEDs versus OXC
group), visit (baseline versus follow up), and interaction
Group × Visit. Statistical analysis for both groups showed
a significant reduction of seizure frequency between first
visit and last follow up visit (p < 0.0001). The comparison
made between treatment groups and interaction Group ×
Visit is not significant (p = 0.1166 between groups; p =
0.9221 Group × Visit).
Adverse Events
Taking into consideration the first variable of safety, drop
out for side effects, the Fisher exact test showed a signifi-
cant difference between the OXC group and the Tradi-
tional AED group (p = 0.0090)(Odds ratio = 6.303). In
particular, concerning drop-out due to heavy side effects,
only 3 patients in the OXC group and 13 patients of Tra-
ditional AEDs group were forced to stopped the AEDs.
Taking into consideration the second variable of safety,
total incidence of side effects, Fisher exact test showed a
significant difference between the OXC group and the Tra-
ditional AED group (p = 0.0063)(Odds ratio = 5.813). In
particular, four patients had side effects during OXC treat-
ment whereas 15 patients in the Traditional AEDs group
had side effects.
Discussion
Epilepsy is considered the most important risk factor for
long-term disability in brain tumour patients [23]. Unfor-
tunately, the side effects related to antiepileptic drugs can
seriously affect the patients' quality of life; in fact, it has
been found that patients' concerns with the AEDs' side
effects have often taken precedence over their desire to
reduce seizure frequency [24]. Side effects are mostly asso-
ciated with the administration of traditional, older AEDs
[3-8]. The few studies which have been done on the newer
AEDs indicate that these same side effects are less frequent
with these drug [9-13]. To date, a comparative study of
this type has not been done.
We performed a statistical analysis and applied a Propen-
sity Score in order to minimize the selection bias and
other sources of bias. Concerning efficacy, results showed
no major differences between the two groups. Concerning
safety and tolerability, however, the profiles differ signifi-
cantly. The traditional AED group had had more side
effects than the OXC group (42.9% vs 11.4%), including
heavy side effects which led patients to discontinue usage
of the AED. It is generally accepted that the percentage of
patients withdrawing because of adverse effects represents
a reliable marker of tolerability [25].
The percentage of side effects for OXC was similar to that
observed in non-tumoral, epileptic patients (10%)[19],
and the percentage of side effects for traditional AEDs is
consistent with literature data (5 to 38% in patients with
brain tumor-related epilepsy)[3].
The most common side effects we found were rash
(11.4% in Traditional AEDs group and 8.6% in OXC
group) and psychomotor slowness (21.7% only in Tradi-
tional AEDs group). In epileptic, non-tumoral patients,
rash is a common side effect associated with most AED
use, ranging between 3–10% and has been the leading
cause of withdrawal from some AED trials [6,26]. The
available data to date indicate that in patients with brain
tumor-related epilepsy, the incidence of severe rash is
higher than in non-tumoral, epileptic patients (14%)[3].
This is in part due to the fact that patients with brain
tumor often undergo radiotherapy and chemotherapy
and this association induces an increased incidence of
skin reactions in patients assuming old AEDs like PHT,
CBZ and PB [4]. Our results are consistent with these lit-
erature data. Regarding psychomotor slowness our results
are consistent with literature data that shows that patients
with brain tumor-related epilepsy taking CBZ, VPA, PB
and PHT performed worse in all cognitive domains than
patients who did not undergo any AED therapy [6]. It is
important to note that literature data cites cognitive
impairment in brain tumor patients as much more com-
mon than the physical disability [27,28]. Such impair-
ment is the major variable which influences quality of life
in patients with epilepsy [29]. For this reason, the choice
of an AED which does not impair cognitive functioning is
of primary importance for patients with brain tumor-
related epilepsy.
Concerning efficacy, we observed a similarly good profile
of efficacy over time in the two groups of treatment, with
a significant reduction in number of seizures. However,
the comparison between treatment groups is not signifi-
cant. Studies to date dedicated specifically to the efficacy
of the new AEDs in controlling seizures in patients with
brain tumor-related epilepsy, are very recent [9-12].
In the literature only one study examined OXC mono-
therapy only in patients with brain tumor-related epilepsy
[11]. This study was conducted for preventing periopera-
tive seizures in patients with brain tumors. In the other
studies, OXC is one of many drugs tested [14,15,30].Journal of Experimental & Clinical Cancer Research 2009, 28:60 http://www.jeccr.com/content/28/1/60
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Recently, one study was done using OXC monotherapy in
patients with cryptogenetic or symptomatic epilepsy [31].
In this study the efficacy of OXC is significantly more pro-
nounced in patients with cryptogenetic epilepsy than in
patients with brain tumors. Our study is the first that uses
only OXC in epilepsy related to brain tumor, with a long-
term follow up and with a good efficacy.
With regard to follow-up, it is important to point out the
difficulty that the death of patients poses in studies of
patients with this type of cancer. It should be noted that
the mortality rate of patients with brain tumors makes
long-term studies difficult and presents problems already
at the onset with obtaining a significant number of partic-
ipants for studies. In the two groups, the follow up varied
from 2 to 48 months: this variability is due to deceased
patients. This has already been mentioned as being a seri-
ous drawback to studies on this patient population.
In our study, both groups of patients were in treatment
with chemotherapy, and data in the literature indicate
that chemotherapy could play a role in seizure control
[32]. Therefore, the fact that systemic therapy might have
affected the outcome cannot be excluded.
In our study we have patients with different histological
diagnosis, so we were unable to determine a difference in
efficacy of AED therapy (traditional and OXC) in control-
ling seizures, based on the different histological diagnosis.
While we used the Propensity Score Technique to avoid
selection bias, we cannot exclude the fact that data
obtained in retrospective studies may affect the outcome
concerning significant statistical differences in efficacy
between the two groups.
Conclusion
This is the first study which compares the older AEDs with
a newer AED, in patients with brain tumor-related epi-
lepsy. Our most significant findings concern the presence
of side effects, both serious and less serious in patients
who had assumed the older AEDs. It was the serious side
effects which were largely present in the traditional AEDs
group; the extent to which patients with these side effects
were forced to interrupt treatment. This brings us to the
issue of patients' quality of life, which we urge must take
into consideration not only seizure control, but also
adverse events; most studies to date focus primarily on the
former and not the latter. Our study clearly demonstrates
that while both traditional AEDs and oxcarbazepine may
reduce seizure frequency equally as well, the higher inci-
dence of serious side effects which make the traditional
AEDs less tolerable, affect the quality of life of patients
who must already face numerous drug therapies.
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